2015 LAM Foundation International Lymphangioleiomyomatosis Conference

 描述（由申请人提供）：LAM基金会2015年淋巴管平滑肌瘤病国际研究会议将重点关注女性致命肺部疾病淋巴管平滑肌瘤病（LAM）中发生的平滑肌增殖和囊性肺破坏的分子机制。这是第十八届LAM会议，它已经从一个专门的家庭/患者会议发展成为LAM和结节性硬化症的最先进的科学会议。针对2012年R13提案的评审员的担忧，他们评论说，改变地点可能会提高出席率，吸引新的研究人员和患者，去年在芝加哥举行的会议取得了压倒性的成功。2015年的会议也将在芝加哥举行。基础科学会议将集中在淋巴管生成和淋巴成像，mTOR信号，LAM生物标志物和以患者为中心的研究设计。更多的临床导向的谈话和案例研究将被纳入会议，以解决有关疾病治疗的实际挑战，肺移植特有的问题以及从其他疾病中吸取教训后LAM生物标志物和表型方法的发展。同时举行的以患者为中心的会议将为预计的280名LAM患者和家庭成员解决关键的临床和生活质量问题。来自科学和临床会议的主要思想领袖将提供他们研究的翻译解释，并参加与患者和家属的讨论小组。该活动将在基础和临床跟踪主席沿着与专家小组进行问答的科学会议总结中达到高潮。LAM的研究人员和临床医生将有多种机会在为期三天的活动中与患者和家属进行非正式的互动。最后一天举行科学圆桌讨论会 审查会议的主要成果并规划今后的会议。每次会议将由该领域的一名专家主持，并将邀请演讲者以及从提交的摘要库中挑选的演讲者。一直有意识地努力吸引来自相关学科的成熟调查人员，他们可以补充现有的LAM调查人员的专业知识。由讨论带头人主持的讨论将是所有会议的重要组成部分。优秀的初级研究人员将根据成绩获得旅费赠款，并有机会以平台和海报形式介绍他们的研究。本次会议的目标是为领先的专家提供一个论坛，讨论LAM的分子和细胞基础，审查LAM的临床管理，介绍前沿研究，整合概念并确定创造性和创新性的研究方向。

 DESCRIPTION (provided by applicant): The LAM Foundation 2015 Lymphangioleiomyomatosis International Research Conference will focus on the molecular mechanisms of smooth muscle proliferation and cystic lung destruction that occur in the fatal lung disease of women, Lymphangioleiomyomatosis (LAM). This is the eigthteenth LAM conference, which has evolved from a dedicated family/patient conference to a state of the art scientific meeting for LAM and tuberous sclerosis. In response to concerns of reviewers of the 2012 R13 proposal who commented that a change in venue may enhance attendance and attract new researchers and patients, the meeting last year was held in Chicago was an overwhelming success. The 2015 conference will also be held in Chicago. The basic science sessions will focus on lymphangiogenesis and lymphatic imaging, mTOR signaling, LAM biomarkers and patient centered research designs. More clinically oriented talks and case studies will be incorporated into sessions, to address practical challenges regarding treatment of the disease, issues unique to lung transplantation and the development of biomarkers and phenotyping approaches for LAM following lessons learned from other diseases. A concurrent patient-centered conference will address key clinical and quality of life issues for an expected 280 LAM patients and family members. Key thought leaders from the scientific and clinical sessions will offer translational interpretations of their research and participate on discussion panels with patients and families. The event will culminate in a summary of scientific sessions presented by the Basic and Clinical Track Chairs along with a panel of experts for Q & A. LAM researchers and clinicians will have multiple opportunities to informally interact with patients an families throughout the three day event. A scientific roundtable discussion is held on the last day of the conference to review the key outcomes of the conference and to plan future conferences. Each session will be chaired by an expert in the field and will have invited speakers as well as speakers chosen from the pool of submitted abstracts. There has been a conscious effort to attract established investigators from related disciplines who can complement the expertise of the current pool of LAM investigators. Discussion facilitated by a discussion leader will be an important component of all sessions. Outstanding junior investigators will be awarded travel grants based on merit and will be given the opportunity to present their research in platform and poster formats. The goal of this conference is to provide a forum for leading experts to discuss the molecular and cellular basis of LAM, review the clinical management of LAM, to present cutting edge research, to integrate concepts and to identify creative and innovative research directions.